Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AGT | P01019 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443610 | 0.84 | NPSR1 (0.38) | ALDH1A1SMN1; SMN2TSHRNPSR1POLB | |
| SCHEMBL3838617 | 0.82 | AGTR1 (0.41) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL8698703 | 0.80 | AGTR1 (0.47) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL29100376 | 0.80 | HSD11B1 (0.36) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9272605 | 0.79 | KCNN4 (0.49) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL635 | 0.78 | AGTR1 (0.51) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL13369361 | 0.78 | AGTR1 (0.39) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2447241 | 0.78 | KCNN4 (0.43) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL3880938 | 0.78 | ALDH1A1 (0.49) | AGTR1AGTR2ALDH1A1SMN1; SMN2HSD11B1 | |
| SCHEMBL7355630 | 0.77 | KCNN4 (0.50) | AGTR1AGTR2ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838683-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-11-23 | — | — | US | claimed |
| EP-2189457-A1 | Novel synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-05-26 | — | — | EP | claimed |
| US-20090216026-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2009-08-27 | — | — | US | claimed |
| EP-2039693-A2 | Novel synthesis of irbesartan | Teva Pharmaceutical Industries Limited (IL) | 2009-03-25 | — | — | EP | claimed |
| EP-1509517-B1 | NOVEL SYNTHESIS OF IRBESARTAN | TEVA PHARMA (IL) | 2008-06-11 | — | — | EP | claimed |
| EP-1812411-A2 | PROCESS FOR PREPARING VALSARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-01 | — | — | EP | claimed |
| US-7227026-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-05 | — | — | US | claimed |
| US-20070117987-A1 | Process for preparing valsartan | TEVA PHARMACEUTICALS USA, INC. | 2007-05-24 | — | — | US | claimed |
| US-7217825-B2 | Synthesis of irbesartan | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-05-15 | — | — | US | claimed |
| WO-2007005967-A2 | PROCESS FOR PREPARING VALSARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-01-11 | — | — | WO | claimed |
| US-20060135780-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2006-06-22 | — | — | US | claimed |
| US-20060135544-A1 | Novel synthesis of irbesartan | NISNEVICH GENNADY | 2006-06-22 | — | — | US | claimed |
| EP-1509517-A2 | NOVEL SYNTHESIS OF IRBESARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-03-02 | — | — | EP | claimed |
| US-20040192713-A1 | Novel synthesis of irbesartan | TEVA PHARMACEUTICALS USA, INC. | 2004-09-30 | — | — | US | claimed |
| WO-2004065383-A2 | NOVEL SYNTHESIS OF IRBESARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-05 | — | — | WO | claimed |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-5155117-A | Hypotensive agents | G. D. SEARLE & CO. (US) | 1992-10-13 | — | — | US | disclosed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135544-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885ALDH1A1 731/4885 |
| US-20070117987-A1 | Process for preparing valsartan | REN, PREP, AVPR2 | AGTR1 16/4885AGTR2 32/4885ALDH1A1 3016/4885 |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | AGTR1 1326/4885AGTR2 940/4885ALDH1A1 373/4885 |
| US-20040192713-A1 | Novel synthesis of irbesartan | REN, AGTR1, AGTR2 | AGTR1 2/4885AGTR2 3/4885ALDH1A1 1102/4885 |
| US-12145927-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | AGTR1 1230/4885AGTR2 870/4885ALDH1A1 508/4885 |
| US-20060135780-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885ALDH1A1 731/4885 |
| US-20090216026-A1 | Novel synthesis of irbesartan | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885ALDH1A1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.